The January issue of SNPits, the University of Florida’s Personalized Medicine Program e-newsletter, summarizes pharmacogenetics studies.
The first is a 2009 article from the journal Gastroenterology. The authors conducted a multi center, randomized controlled trial whereby patients were given high or low-dose celecoxib, or placebo, and were followed up with colonoscopies at one and three years. The authors reported that risk of cardiovascular adverse events may be influenced by CYP2C9 genotype, and that risk of developing adenoma may not differ by high vs. low dose celecoxib for all genotypes. The authors conclude that further research into the implications of CYP2C9 genotype for the routine use of celecoxib is needed.
Read the summary here: http://personalizedmedicine.ufhealth.org/2016/01/04/celecoxib-cyp2c9-variability-influences-colorectal-adenoma-prevention/
The second is from 2015 and comes from the journal Thrombosis Research. The authors measured residual platelet reactivity (RPR) in coronary heart disease patients who were on duel anti platelet therapy (aspirin and clopidogrel). Some patients were also taking esomeprazole, a proton pump inhibitor. Clopidogrel is activated by CYP2C19, and esomeprazole is a major substrate of CYP2C19. The authors investigated whether concomitant use of esomeprazole and clopidogrel, as well as whether polymorphisms in CYP2C19 in patients taking esomeprazole and clopidogrel had any influence on RPR or adverse events. The authors reported that concomitant use of esomeprazole and clopidogrel had no significant effect on RPR, or outcomes regardless of CYP2C19 phenotype as compared to patients not taking esomeprazole. However, RPR did vary according to the number of CYP2C19 loss of function alleles in a patient, regardless of esomeprazole use.
Read the summary here: http://personalizedmedicine.ufhealth.org/2016/01/15/clopidogrel-effect-of-esomeprazole-on-platelet-activity-clinical-outcomes/
The first is a 2009 article from the journal Gastroenterology. The authors conducted a multi center, randomized controlled trial whereby patients were given high or low-dose celecoxib, or placebo, and were followed up with colonoscopies at one and three years. The authors reported that risk of cardiovascular adverse events may be influenced by CYP2C9 genotype, and that risk of developing adenoma may not differ by high vs. low dose celecoxib for all genotypes. The authors conclude that further research into the implications of CYP2C9 genotype for the routine use of celecoxib is needed.
Read the summary here: http://personalizedmedicine.ufhealth.org/2016/01/04/celecoxib-cyp2c9-variability-influences-colorectal-adenoma-prevention/
The second is from 2015 and comes from the journal Thrombosis Research. The authors measured residual platelet reactivity (RPR) in coronary heart disease patients who were on duel anti platelet therapy (aspirin and clopidogrel). Some patients were also taking esomeprazole, a proton pump inhibitor. Clopidogrel is activated by CYP2C19, and esomeprazole is a major substrate of CYP2C19. The authors investigated whether concomitant use of esomeprazole and clopidogrel, as well as whether polymorphisms in CYP2C19 in patients taking esomeprazole and clopidogrel had any influence on RPR or adverse events. The authors reported that concomitant use of esomeprazole and clopidogrel had no significant effect on RPR, or outcomes regardless of CYP2C19 phenotype as compared to patients not taking esomeprazole. However, RPR did vary according to the number of CYP2C19 loss of function alleles in a patient, regardless of esomeprazole use.
Read the summary here: http://personalizedmedicine.ufhealth.org/2016/01/15/clopidogrel-effect-of-esomeprazole-on-platelet-activity-clinical-outcomes/
No comments:
Post a Comment